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–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Objective: The aim of this study was to investigate the expression of cannabinoid receptors in hu-
man uterine smooth muscle during pregnancy and to evaluate the eﬀects of endogenous and ex-
ogenous cannabinoids on myometrial contractility in vitro.
Study design: Human myometrial biopsy specimens were obtained at elective cesarean delivery
and snap frozen or mounted for isometric recording under physiologic conditions. Cumulative
doses of the endogenous cannabinoid anandamide or the exogenous cannabinoid D9 (indicates
a double bond between carbons 9 and 10) tetrahydrocannabinol were added in the range
1 nmol/L to 100 mmol/L. Selectivity of the cannabinoid receptor agonists was investigated with
speciﬁc antagonists for the CB1 and the CB2 receptors. Reverse transcriptionepolymerase chain
reaction with primers for the CB1 and CB2 receptors was performed on messenger RNA that was
isolated from human pregnant myometrium.
Results: Both anandamide and D9-tetrahydrocannabinol exerted a direct relaxant effect on
human pregnant myometrium in vitro, which was of equal potency for both compounds. This re-
laxant effect was antagonized by the speciﬁc CB1 receptor antagonist, SR 141716, but not by the
speciﬁc CB2 receptor antagonist, SR 144528 (n=6 specimens, P!.01). Both the CB1 and CB2
receptors are expressed in human myometrium.
Conclusions: Both endogenous and exogenous cannabinoids exert a potent and direct relaxant
eﬀect on human pregnant myometrium, which is mediated through the CB1 receptor. This high-
lights a possible role for endogenous cannabinoids during human parturition and pregnancy.
These results also support the view that the use of exogenous cannabinoids during pregnancy
is not linked independently with preterm labor.






–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––There has been a marked increase in marijuana (can-
nabis) use during pregnancy in the last 20 years.1-3 This
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doi:10.1016/j.ajog.2003.07.013increase has raised questions about its potential adverse
effects for the mother and developing fetus.3-7 Speciﬁc
problems (such as low fetal birth weight, preterm deliv-
ery, miscarriage, stillbirth, congenital malformation,
and neonatal complications) have been associated with
cannabis use during pregnancy,3-8 with evidence that
frequent or regular use is more hazardous than occa-
sional use.2
Dennedy et al 3The principal biologically active component of mari-
juana, D9-tetrahydrocannabinol (D9-THC), is a member
of the cannabinoid family, which is known to exert the
effects by way of the cannabinoid receptor subtypes,
CB1 and CB2.
8,9 In 1992, after the discovery of the can-
nabinoid receptors, it was reported that arachidonoyl
ethanolamine, also known as anandamide, is an endoge-
nous ligand for these receptors (ie, an endogenous canna-
binoid or endocannabinoid).10 Since then much research
has focused on the role and effects of cannabinoids in dif-
ferent tissue systems.11-13 Little is known about the direct
effects of cannabinoids on human reproductive tissues.
In rats, it has been shown that the administration of
anandamide or D9-THC prolonged the duration of preg-
nancy and increased the frequency of stillbirths.14,15 It
was suggested that this prolongation of pregnancy in rats
may be linked to a reduction in uterine prostaglandin
synthesis. However, CB1 and CB2 receptors are coupled
through Gi/o proteins to other intracellular signaling
pathways (such as adenylate cyclase, mitogen-activated
protein kinase, and ion channels)16-18 and therefore
may have the ability to modulate uterine contractility
directly. The aims of this study were to investigate for
expression of the CB1 and CB2 receptors in human
uterine smooth muscle (myometrium) that was obtained
during pregnancy, to evaluate the direct effects of the
cannabinoids anandamide and D9-THC on human uter-
ine contractility during pregnancy, and to determine
whether the uterine effects of these cannabinoids were
mediated by the stimulation of the CB1 or CB2 receptors.
Methods
Tissue collection
Biopsy specimens of human myometrial tissue during
pregnancy were obtained at elective cesarean delivery
(ie, women not in labor) performed at term (37-42 weeks
of gestation, n=11 women). The biopsy specimens were
excised from the upper midline portion of the incision in
the lower uterine segment. Ethical committee approval
was obtained from the Research Ethics Committee at
University College Hospital, Galway, and recruitment
was by written informed consent. Immediately on collec-
tion, the tissue for organ bath studies was placed in
Krebs-Henseleit physiologic salt solution of the follow-
ing composition: potassium chloride 4.7 mmol/L,
sodium chloride 118 mmol/L, magnesium sulfate 1.2
mmol/L, calcium chloride 1.2 mmol/L, potassium phos-
phate 1.2 mmol/L, sodium bicarbonate 25 mmol/L, and
glucose 11 mmol/L (Sigma-Aldrich, Dublin, Ireland).
Tissue for the organ bath studies was stored at 4(C
and used within 12 hours of collection. Immediately
on collection tissue for RNA extraction was rinsed in
normal saline solution, snap frozen in liquid nitrogen,
and stored at 70(C.Myometrial tissue bath experiments
Longitudinal myometrial strips were dissected, measur-
ing approximately 2! 2! 10 mm, and mounted under
2g of tension in organ tissue baths for isometric re-
cording as previously described.19-21 Each tissue bath
contained 20 mL of Krebs-Henseleit physiologic salt
solution, which was maintained at 37(C, pH 7.4, and
gassed continuously with a mixture of 95% oxygen/
5% carbon dioxide. The strips were allowed to equili-
brate for at least 1 hour before the addition of oxytocin
as a uterotonic agent. The Krebs-Henseleit physiologic
salt solution in the tissue baths was changed every 15
minutes during the equilibration period. After equilibra-
tion, contractions were stimulated by bath exposure of
the strips to oxytocin (0.5 nmol/L) for a period of 30
minutes, until regular phasic contractions were achieved.
Bath addition of either the selective CB1 antagonist SR
14171622 or the selective CB2 antagonist SR 144528
23 or
of the respective vehicle for each antagonist was then
performed for a further 30-minute period. This was
followed by the addition of the endocannabinoid anan-
damide or the exogenous cannabinoid D9-THC, in a
cumulative manner, at bath concentrations in the range
1 nmol/L to 100 mmol/L (ie, 109-104 mol/L) at 20-
minute intervals. The cumulative increases in bath con-
centration of anandamide or D9-THC were achieved in
a pattern of 1 log molar increase every 20 minutes (ie,
1 nmol, 10 nmol, 100 nmol). Control experiments that
tested for tachyphylaxis, with a single dose for a similar
time period, revealed no difference between isolated
exposure and cumulative exposure during this time.
The mechanical response of tissues was measured by
the calculation of the integral of selected areas for 20-
minute periods with the PowerLab hardware unit (AD
Instruments, Oxfordshire, UK) and Chart software (ver-
sion 3.6; AD Instruments). The integrated tension for
the 20-minute period before the addition of cannabi-
noid, either anandamide or D9-THC, was calculated,
and this value served as a control because no signiﬁcant
spontaneous reduction in myometrial contractility was
observed over the duration of the experiments in the
control strips. The effects of anandamide and D9-THC,
in the presence or absence of antagonist, were assessed
by the integral that was calculated during the 20-minute
period after the addition of each drug concentration and
given as a percentage of the integral that was obtained in
the 20-minute period before any drug addition (ie, per-
centage contractility).
RNA extraction and reverse transcription
Total RNA was isolated with TRIzol reagent (Life
Technologies, Grand Island, NY).24 RNA was then re-
verse transcribed into complementary DNA (cDNA)
for use as a template for polymerase chain reaction
(PCR). One microgram of RNA was DNAase I treated
4 Dennedy et al(Ambion Inc, Austin, Tex). The RNA samples were then
denatured at 65(C for 10 minutes. Reverse transcription
was performed at 42(C for 60 minutes in a reaction vol-
ume of 20 mL that contained oligo dT primer (500 ng),
Maloney murine leukemia virus, reverse transcription
buffer (50 mmol/L TRISehydrochloric acid, pH 8.3,
75 mmol/L potassium chloride, 3 mmol/L magnesium
chloride, 10 mmol/L dithiothreitol; Promega, Madison,
Wis), diethylpyrocarbonate-treated water (BDH, Dor-
set, UK), deoxyribonucleotide triphosphates (0.1 mmol/
L; Promega), and 200 mMaloney murine leukemia virus
reverse transcriptase (Promega). Reverse transcriptase
activity was stopped when the samples were heated at
65(C for 10 minutes. Control RNA samples, in which
no reverse transcription enzyme was added, were in-
cluded to conﬁrm that no genomic DNA contamination
was present.
PCR
The 5 mL of each 20-mL reverse transcriptase reaction
was then used in subsequent PCR reactions. PCR was
performed in a ﬁnal volume of 50 mL that contained
1.5mmol/L magnesium chloride, 20 mmol/L TRISe
hydrochloric acid, 50 mmol/L potassium chloride, pH
8.3 (Life Technologies), 1.25 m Taq DNA polymerase
(Life Technologies), 40 mmol/L deoxyribonucleotide tri-
phosphates (Promega), and 0.2 pmol of each sense and
antisense primer. cDNA ampliﬁcation was carried out
by an initial denaturation step of 5 minutes at 95(C fol-
lowed by 40 cycles of denaturation at 94(C for 20 sec-
onds, annealing at 60(C for 45 seconds, and elongation
at 72(C for 20 seconds. The 5 mL of each PCR product
was then separated by gel electrophoresis on a 1.2% aga-
rose gel. Products were run alongside a 100-bpDNAmass
ladder (Sigma-Aldrich, Dublin, Ireland) for sizing. Pri-
mers that were used were designed according to published
DNA and messenger RNA (mRNA) sequences from
GenBank (Los Alamos, NM; CB1 receptor accession
code U73304, CB2 receptor accession code X74328).
Drugs and solutions
A stock solution of oxytocin (1 mmol/L, Sigma-Aldrich)
was made in ethanol. Anandamide and D9-THC were
obtained from Sigma-Aldrich (St Louis, Mo). A stock
solution (102 mol/L) of anandamide or D9-THC was
prepared with ethanol. The series of dilutions were made
with deionized water on the day of the experimentation
and were maintained at room temperature for the dura-
tion of the experiment. Fresh Krebs-Henseleit physio-
logic salt solution was made daily. SR 141716 was
donated by B. R Martin, PhD, Virginia Commonwealth
University, and also by Sanoﬁ Recherche, Montpellier
France. The SR 144528 was donated by Sanoﬁ Re-
cherche. Stock solutions (103 mol/L) of all three com-
pounds were made with deionized water. A license wasobtained for the possession and importation of D9-
THC under the ‘‘Misuse of Drugs Acts, 1977 and
1984’’ and the ‘‘Misuse of Drugs Regulations, 1988’’
as set down by the government of the Republic of
Ireland.
Statistical analysis
With the calculated integrals of contractile activity at
each bath, the concentration dose response curves were
analyzed by ﬁtting the logistic equation: Y=Y max !
DnH/EC50+D
n
H, where Y is the response (percentage
contractility), Y max is the maximal relaxation achieved,
D is the dose of agonist (anandamide or D9-THC), nH is
the slope function, and EC50 is the agonist dose giving
one-half the maximal response. Curve ﬁtting was per-
formed with the software package Prism (Graphpad
Software, San Diego, Calif). For myometrial tissue,
the concentration of agonist (ie, anandamide or D9-
THC) that resulted in one half the maximal inhibitory
effect (ie, the EC50) was measured and represented in
pharmacologic terms as its appropriate log10 value
(ie, log10 EC50), which is also known as the pD2. For
example, if the EC50 value were 1 mmol/L (ie, 10
6
mol/L), the pD2 would be 6.0. Comparisons of pD2
(log EC50) and mean maximal inhibitory (MMI) re-
sponse values were carried out with a two-way analysis
of variance. Post hoc comparisons were made with the
Newman-Keuls test. A probability value of !.05 was
accepted as statistically signiﬁcant. The statistical pack-
age GBSTAT (version 6.5; Dynamic Microsystems Inc,
Silver Spring, Md) was used for statistical calculations.
Results
Myometrial biopsy specimens were obtained from 11
women who underwent cesarean delivery between 38
and 40 weeks of gestation (median gestation, 39 weeks).
All cesarean deliveries were carried out electively for the
following reasons: breech presentation, previous cesa-
rean delivery, previous myomectomy, previous shoul-
der dystocia, placenta previa, and fetal intrauterine
growth restriction. The mean maternal age at delivery
was 34.7 years (range, 21-37 years). The median parity
value of the women at the time of delivery was 1 (range,
0-3). All women had regional anesthesia for cesarean
delivery.
Both anandamide and D9-THC exerted a signiﬁcant
concentration-dependent relaxant effect on human myo-
metrial contractility in vitro. Recordings of oxytocin-
induced myometrial contractions and the effects of
cumulatively increasing concentrations of anandamide
and D9 THC are shown in Figures 1, A, and 2, A, respec-
tively. For anandamide, the pD2 value was 5.58G 0.42
(n=6 specimens), the MMI response value was
Dennedy et al 5Figure 1 Representative recordings of oxytocin-induced con-
tractions in human myometrial strips and the effects of anandamide
are shown. A, The relaxant effect of anandamide (ANAN) in
myometrium is not preincubated with antagonist. B, Antag-
onism of the effects of anandamide in the presence of the CB1
antagonist SR 141716 is shown. C, No antagonism was
observed with the CB2 antagonist SR 144528.Figure 2 Representative recordings of oxytocin-induced con-
tractions in human myometrial strips and the effects of D9-THC are
shown. A, The relaxant effect of D9-THC in myometrium is not
preincubated with antagonist. B, Antagonism of the effects of
D9-THC in the presence of the CB1 antagonist SR 141716 is
shown. C, No antagonism was observed with the CB2
antagonist SR 144528.Table I Uterorelaxant effect of the cannabinoid agents in the absence and presence of antagonist
No antagonist +SR 141716 (CB1 anatgonist) +SR 144528 (CB2 antagonist)
Agonist pD2 MMI pD2 MMI pD2 MMI
D9-THC 5.19G0.91 75.05G1.15 2.57G0.18* 34.44G2.28* 5.73G0.30 74.07G3.72
ANAN 5.58G0.42 75.75G2.20 2.95G0.14* 38.39G2.08* 6.21G0.29 75.43G1.95
Data expressed as meansGSEM.
* P!.01 versus antagonist-treated counterparts.75.74%G2.20% (n=6 specimens), and the correspond-
ing values for D9-THC were 5.20G0.94 (n=6 speci-
mens) and 75.04%G1.15% (n=6 specimens, Table I).
There was no signiﬁcant difference between the poten-
cies of both compounds.
The selective CB1 antagonist SR 141716 produced
a parallel rightward shift of the dose response curve
for both anandamide (Figure 3, A) and D9-THC (Figure
3, B), which indicated antagonism of their effects. Ex-
amples of raw data recordings of myometrial contrac-
tions in vitro that demonstrated antagonism by SR
141716 are shown in Figures 1, B, and 2, B, for ananda-
mide and D9-THC, respectively. There was a signiﬁcant
difference between the pD2 values for both anandamide
and D9-THC in the absence and presence of SR141716(n=6 specimens, P!.01, Table I). There was also a sig-
niﬁcant difference between the MMI response values for
both anandamide and D9-THC in the absence and pres-
ence of SR141716 (n=6 specimens, P!.01, Table I).
On the contrary, the CB2 antagonist SR 144528 did
not result in any signiﬁcant alteration in the dose re-
sponse curve for either anandamide or D9-THC, as dem-
onstrated in Figures 1, C, and 2, C, respectively, and
also in Figure 3, A and B, respectively. There was no sig-
niﬁcant difference between the pD2 values or the MMI
response values for either anandamide or D9-THC in
the presence or absence of SR 144528 (Table I).
Reverse transcriptase reaction products were sub-
jected to PCR ampliﬁcation with oligonucleotide primer
sets that corresponded to both cannabinoid receptor
6 Dennedy et alsubtypes. Both primer sets yielded PCR products of the
expected sizes (n=2 sets, Figure 4 and Table II). Am-
pliﬁcation with the CB1 primer set resulted in a 345-bp
PCR product. This product was sequenced (MWG-Bio-
Figure 3 A, The dose response curves demonstrates the
uterorelaxant effect of the endogenous cannabinoid, ananda-
mide alone (closed circles) and with bath pre-exposure to the
CB1 receptor antagonist SR 141716 (open squares) or the CB2
receptor antagonist SR 144528 (closed squares). B, The dose-
response curves demonstrate the uterorelaxant effect of the
exogenous cannabinoid, D9-THC alone (closed squares) and
with bath pre-exposure to SR 141716 (open squares) or SR
144528 (closed circles). Percentage contractility is shown on
the y-axis, and the concentration of agonist is shown on the
x-axis. The points represent the means, and the error bars
represent the SEM.tech Ltd., Milton Keynes, UK), and the results veriﬁed
that it was a part of the CB1 receptor gene. Ampliﬁca-
tion of myometrial cDNA with CB2 primers yielded
a 439-bp product for which sequence analysis conﬁrmed
it to be part of the CB2 receptor gene sequence. PCR of
the reverse transcriptase negative controls showed no
ampliﬁcation that conﬁrmed no genomic DNA contam-
ination. Similarly, the PCR negative control (no cDNA
template) showed no ampliﬁcation product.
Comment
This is the ﬁrst demonstration of the presence of canna-
binoid receptors in human uterine smooth muscle and
the ﬁrst report that outlines that the endogenous canna-
binoid anandamide and the exogenous cannabinoid D9-
THC exert a potent relaxant effect on oxytocin-induced
human myometrial contractility. Endogenous cannabi-
noids have been the subject of much research interest
in vascular11 and nonvascular12 smooth muscle systems
in recent years. Little is known about the role of endog-
enous cannabinoids in human reproduction. In the
mouse, it has been suggested that the aberrant synthesis
of anandamide or the aberrant expression of cannabi-
noid receptors in the uterus or embryo may account
for early pregnancy failure or female infertility.25 Simi-
larly, low fatty acid amide hydrolase activity, the anan-
damide degrading enzyme, has been implicated as
a cause of implantation failure and pregnancy loss in
humans.26 In rats it has been demonstrated that the ad-
ministration of endogenous (anandamide) or exogenous
(D9-THC) cannabinoids results in an increase in the du-
ration of pregnancy and in the frequency of stillbirths.15
It was suggested that this may be due to the central
effects of the cannabinoids. Our ﬁndings demonstrate
a clear direct effect of endogenous and exogenous can-
nabinoids on myometrial function and raise questions
about a possible role of endogenous cannabinoids in
the maintenance of uterine quiescence during normal
pregnancy.
We have shown that the relaxant effect of the endog-
enous and exogenous cannabinoids in human uterine
smooth muscle appears to be mediated predominantly
through the CB1 receptor. Previously CB1 mRNA has
been detected in the central nervous system and in pe-
ripheral tissues that include heart, lung, bladder, and ad-
renal gland.16,27 In vascular tissues, the vasodilatation
and hypotension that is elicited by endocannabinoids
appear to be also mediated through the CB1 re-
ceptor.11,28 In the gastrointestinal system, the activa-
tion of CB1 receptors inhibits gastrointestinal motility,
intestinal secretion, and gastric acid secretion.27 The
proposed signal transduction pathways that are linked
to cannabinoid receptor agonists include the inhibition
of N-type and P/Q-type voltage sensitive calcium
Dennedy et al 7Figure 4 Representative agarose gel that was stained with ethidium bromide demonstrates the expression of CB1 mRNA (A) and CB2
mRNA (B) in human pregnant (n=2 specimens) and nonpregnant (n=2 specimens) myometrium. Reverse transcriptaseenegative
(RT) controls for each candidate gene are shown alongside reverse transcriptaseepositive (RT+) PCR products. A water control
is also included (no cDNA template). M, 100-bp marker.channels and the activation of inwardly rectifying potas-
sium channels, which would lead to membrane hyperpo-
larization and the inhibition of contractile activity.27
The mechanisms that are operative in human uterine tis-
sue, which result in the degree and potency of relaxation
observed in this study, remain a topic for future re-
search. Little is known about the physiologic role of
the CB2 receptors, but CB2 mRNA is present mainly
in immune cells with particularly high levels in B cells
and natural killer cells,29 which suggests an immuno-
modulatory role. Although we have demonstrated CB2
mRNA in human myometrium during pregnancy, the
CB2 receptor did not appear to have a major role in
the relaxant effect that is elicited by cannabinoids.
Approximately 5% of women admit to using cannabis
during pregnancy,2,30 but it is believed that this ﬁgure
underestimates the true prevalence of cannabis smokingat this time. According to previously measured serum
concentrations of D9-THC in the serum of patients after
the intake ofmarijuana, we have estimated that the serum
levels would be in the micromolar range, which lies in the
middle of our dose response curve.31,32Our ﬁndings there-
fore suggest that smoking cannabis during pregnancy
would exert a signiﬁcant uterorelaxant effect. The link be-
tween cannabis use during pregnancy and the risk of
Table II Primers used for reverse transcriptionePCR









8 Dennedy et alpreterm delivery has been the focus of much research,
with conﬂicting reports fromdifferent studies.2,33,34 From
a physiologic point of view, our results support the theory
that cannabis use in itself, after standardization for other
socioeconomic variables, should not be an independent
risk factor for preterm delivery. The possibility that regu-
lar use after termmight delay the onset of labor and there-
fore increase stillbirth rates, as shown in animal studies,14
is raised however by our ﬁndings.
The studies that are mentioned here can only be per-
formed in vitro in human uterine tissue for obvious ethi-
cal reasons. There are some limitations in extrapolation
from in vitro studies to the in vivo situation. Our ﬁnd-
ings do not account for a possible central effect of
endogenous and exogenous cannabinoids that, it ap-
pears, may have further relaxant effects on peripheral
smooth muscle tissues.35 The possibility that cannabi-
noid effects on human uterine tissue may be altered dur-
ing pregnancy, in comparison with nonpregnant
myometrium, requires further evaluation. Finally, our
study has focused on the effects on uterine smooth mus-
cle and has not addressed the effects of cannabinoids on
the fetus or the fetoplacental circulation.
In conclusion, endogenous and exogenous cannabi-
noids exert a potent relaxant effect in vitro on human
uterine smooth muscle during pregnancy. This direct
effect is mediated through the CB1 receptor. This
highlights the possibility of a physiologic role for endog-
enous cannabinoids during human pregnancy and par-
turition. Our results support the view that exogenous
cannabis use during pregnancy is not linked indepen-
dently to preterm delivery.
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